Founded in 2005; $28 million invested; five novel lead
compounds discovered. Download our fact sheet for an overview of Amira. PDF
Keep pace with developments at Amira by signing up for
regular email alerts. Sign up here.
|
16-Jun-2010:
How to Find Balance in Biotech, Between Owning It All or Finding a Partner – Xconomy < LINK>
29-Mar-2010:
“Hope ‘4-A’ Break in Asthma; FLAP Made Over New Bids” – BioWorld® Insight discusses new treatments being tested for asthma, including Amira’s 5-lipoxygenase activating protein (FLAP) inhibitors
22-Mar-2010:
“InterMune Likely First To Market In IPF, But Other Firms Poised To Follow” – The Pink Sheet summarizes clinical and preclinical programs for treatment of IPF, including Amira’s LPA1 antagonist
28-Jan-2010:
Amira Mixes Small Biotech Irreverence, With Big Pharma Rigor, To Create New Lung Drugs - Xconomy < LINK>
15-Jan-2010:
Transforming Inflammatory Disease Therapies. Amira's Expertise Lies in Once-Daily Oral Therapies Targeting Bioactive Lipids - Genetic Engineering & Biotechnology News < LINK>
1-Dec-2009:
Developing a New Drug for Idiopathic Pulmonary Fibrosis - Pulmonary Fibrosis Foundation < PDF>
12-Jan-2010:
Bullish New Year's resolutions debut at the J.P. Morgan event - FierceBiotech <
LINK>
|
19-July-2010:
Amira Pharmaceuticals, Inc. announced today that its FLAP (5-lipoxygenase-activating protein) program, which is partnered with GlaxoSmithKline, has achieved two clinical development milestones. , <more>
13-July-2010:
Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2431927, titled, “5-Lipoxygenase Activating Protein (FLAP) Inhibitors,” which includes coverage of Amira’s AM103 and AM803 FLAP inhibitors for the treatment of respiratory disorders. , <more>
26-May-2010:
Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2461629, titled, “HETEROALKYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS,” which includes coverage of Amira’s AM461 DP2 receptor antagonist. , <more>
6-May-2010:
Amira Pharmaceuticals, Inc. announced today that preclinical data from its LPA1 receptor antagonist program has been published in the British Journal of Pharmacology. , <more>
21-April-2010:
Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted it patent number GB2460597 titled “N,NDISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS.” , <more>
11-January-2010:
Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present a company overview at the 28th Annual J.P. Morgan Healthcare Conference. , <more>
7-January-2010:
Amira Pharmaceuticals, Inc. announced today that it has achieved another development milestone in its FLAP program, which is partnered with GlaxoSmithKline. , <more>
3-December-2009:
Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM461, the Company’s second oral selective antagonist of the DP2 (also known as CRTH2) receptor. , <more>
27-October-2009:
Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present a company overview at the 8th Annual BIO Investor Forum. The presentation is scheduled for 2:30 p.m. PDT on Thursday, October 29, at the Palace Hotel in San Francisco, Calif. , <more>
|
